Official Title
Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan
Brief Summary

To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo

Detailed Description

Randomized placebo controlled trial including COVID 19 seropositive patients will be treated
with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in
positive COVID 19 patients.

Blood samples will be taken first at base line level, after two weeks and after the
intervention after satisfying the inclusion and exclusion criteria. The main objective is to
assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients.
The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the
effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease

Unknown status
COVID 19

Dietary Supplement: Acacia Senegal

Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
Other Name: Gum Arabic

Dietary Supplement: Pectin

Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks

Eligibility Criteria

Inclusion Criteria:

- COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly
diagnosed)

Exclusion Criteria:

- Intubated patients on parental treatment

Eligibility Gender
All
Eligibility Age
Minimum: 5 Years ~ Maximum: 90 Years
Countries
Sudan
Locations

Omdurman Teaching Hospital
Khartoum, Omdurman, Sudan

Jabra Hospital,
Khartoum, Sudan

Contacts

Dr Babiker, PhD
+249912951517
rashat33@yahoo.com

Shahenaz Satti, MSc
+249912204825
shahenazsatti@gmail.com

University of Khartoum
NCT Number
Keywords
Gum Arabic
Immunomodulator
MeSH Terms
COVID-19